Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 2
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
10actual
Sites
13
Countries
Australia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
All participants who have received fordadistrogene movaparvovec in any Pfizer study will now be assessed for long-term safety in one combined study: C3391003
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-08-08 | actual | When the study began enrolling |
| Primary completion | 2025-10-03 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-03 | actual | The whole study's end, after follow-up |
| First posted | 2022-06-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Muscular Dystrophy, Duchenne
Intervention
- Genetic: PF-06939926 — also filed as Fordadistrogene Movaparvovec
Primary outcomes
what the primary-completion date above is the date OFIncidence and severity of Treatment-Emergent Adverse Events and Serious Adverse Events
measured Through Week 52
Number of participants with abnormal hematology test results
measured Through Week 52
Number of participants with abnormal biochemistry test results
measured Through Week 52
Number of participants with abnormal urine analysis
measured Through Week 52
Number of participants with abnormal and clinically relevant changes in neurological examinations
measured Through Week 52
Number of participants with abnormal and clinically relevant changes in body weight
measured Through Week 52
Number of participants with abnormal and clinically relevant changes in vital signs
measured Through Week 52
Number of participants with abnormal and clinically relevant changes on cardiac troponin I
measured Through Week 52
Number of participants with abnormal and clinically relevant changes on electrocardiogram (ECG)
measured Through Week 52
Number of participants with abnormal and clinically relevant changes on echocardiogram
measured Through Week 52
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed